Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
7.98
-0.10 (-1.24%)
Aug 7, 2026, 9:30 AM EDT - Market open
Akari Therapeutics, Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2.77 | 5.2 | 2.6 | 3.85 | 13.25 | 9.36 |
Cash & Short-Term Investments | 2.77 | 5.2 | 2.6 | 3.85 | 13.25 | 9.36 |
Cash Growth | 7.20% | 100.19% | -32.41% | -70.98% | 41.55% | -33.40% |
Accounts Receivable | - | 0.44 | - | - | 2.95 | 4.98 |
Other Current Assets | 0.82 | - | 0.35 | 0.5 | - | - |
Total Current Assets | 3.59 | 5.64 | 2.95 | 4.34 | 16.2 | 14.34 |
Other Intangible Assets | 30.3 | 30.3 | 39.18 | 0.01 | 0.02 | 0.02 |
Goodwill | - | - | 8.43 | - | - | - |
Other Long-Term Assets | - | 30.3 | - | - | 0.02 | 0.02 |
Total Assets | 33.89 | 35.94 | 50.56 | 4.36 | 16.22 | 14.36 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 8.64 | 11.62 | 12.41 | 1.67 | - | - |
Accrued Expenses | 3.33 | - | 3.14 | 1.57 | - | - |
Short-Term Debt | 0.73 | 0.67 | 3.01 | - | - | - |
Current Portion of Long-Term Debt | - | - | 0.25 | - | - | - |
Other Current Liabilities | 0.71 | 0.06 | 1.11 | 1.35 | 7.85 | - |
Total Current Liabilities | 13.42 | 12.58 | 19.91 | 4.58 | 7.85 | 6.09 |
Other Long-Term Liabilities | 6.09 | 6.35 | 8.42 | - | - | - |
Total Long-Term Liabilities | 6.09 | 6.12 | 8.42 | - | - | - |
Total Liabilities | 19.51 | 18.71 | 28.33 | 4.58 | 10.98 | 6.09 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | - | - | 5.32 | 1.32 | 0.74 | 0.48 |
Additional Paid-in Capital | 234.81 | 232.67 | 212.71 | 174.75 | - | 125.06 |
Accumulated Other Comprehensive Income | 58.57 | 37.54 | 51.46 | 51.15 | 52.19 | 52.19 |
Retained Earnings | -279.01 | -252.97 | -247.25 | -227.46 | -191.34 | -174.33 |
Shareholders' Equity | 14.38 | 17.23 | 22.23 | -0.23 | 5.24 | 8.27 |
Total Liabilities & Equity | 33.89 | 35.94 | 50.56 | 4.36 | 16.22 | 14.36 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.73 | 0.67 | 3.26 | 0 | 0 | 0 |
Net Cash (Debt) | 2.04 | 4.53 | -0.66 | 3.85 | 13.25 | 9.36 |
Net Cash Growth | 176.63% | - | - | -70.98% | 41.55% | -33.40% |
Net Cash Per Share | - | 5.65 | -2.22 | 12.93 | 0.01 | 0.01 |
Book Value | 14.38 | 17.23 | 22.23 | -0.23 | 5.24 | 8.27 |
Book Value Per Share | 0.00 | 21.49 | 74.75 | -0.77 | 0.00 | 0.01 |
Tangible Book Value | -15.92 | -13.07 | -25.38 | -0.24 | 5.22 | 8.24 |
Tangible Book Value Per Share | -0.00 | -16.29 | -85.35 | -0.82 | 0.00 | 0.01 |